264 related articles for article (PubMed ID: 8925538)
1. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
3. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
4. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
[TBL] [Abstract][Full Text] [Related]
5. [Simvastatin in the treatment of familial hypercholesterolemia].
Ceska R; Sobra J; Procházková R; Kvasilová M
Cas Lek Cesk; 1995 May; 134(10):310-3. PubMed ID: 7788650
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
7. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
Okopień B; Cwalina Ł; Haberka M; Kowalski J; Zieliński M; Szwed Z; Kalina Z; Herman ZS
Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
[TBL] [Abstract][Full Text] [Related]
8. [The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels].
Perova NV; Ozerova IN; Kalinina AM; Pavlova LI; Olfer'ev AM; Mel'kina OE; Golubev MA; Oganov RG
Ter Arkh; 1996; 68(1):71-6. PubMed ID: 8644040
[TBL] [Abstract][Full Text] [Related]
9. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Yesilbursa D; Serdar A; Saltan Y; Serdar Z; Heper Y; Guclu S; Cordan J
Kardiol Pol; 2005 Jun; 62(6):526-30. PubMed ID: 16123850
[TBL] [Abstract][Full Text] [Related]
10. [Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen].
Urbánek R; Coufal Z
Vnitr Lek; 1998 May; 44(5):259-62. PubMed ID: 9820067
[TBL] [Abstract][Full Text] [Related]
11. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia.
Geiss HC; Schwandt P; Parhofer KG
Exp Clin Endocrinol Diabetes; 2002 Jun; 110(4):182-7. PubMed ID: 12058342
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
[TBL] [Abstract][Full Text] [Related]
13. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu J; Ye P
Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
[TBL] [Abstract][Full Text] [Related]
14. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
Márk L; Márki-Zay J; Orosz I; Kondacs A; Erdei F; Katona A
Orv Hetil; 2003 Apr; 144(16):765-8. PubMed ID: 12778627
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
17. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
Ceska R; Stulc T
Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407
[TBL] [Abstract][Full Text] [Related]
18. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Zeman M; Zák A; Vecka M; Romaniv S
Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
[TBL] [Abstract][Full Text] [Related]
19. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
